1/ Klausegger A, Strobl B, Regl G, et al. Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus. J Virology 1999; 73: 3737–3743.
2/ Tyrrell DAJ, Bynoe ML. Cultivation of a novel type of common-cold virus in organ cultures. Br Med J 1965; 1:1467-70. 10.1136/bmj.1.5448.1467 14288084
3/ Lo’aiAlanagreh, FoadAlzoughool and ManarAtoum. The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into PotentialDrugs and Its Mechanisms. Pathogens 2020, 9, 331; doi:10.3390/pathogens9050331
4/ van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med. 2004; 10:368–73
5/ 5/ Lewis, Nathaniel M., et al. "Household transmission of SARS-CoV-2 in the United States." Clinical infectious diseases: an official publication of the Infectious Diseases Society of America (2020).
6/ Parry, Richard Lloyd. "Travel alert after eighth camel flu death." The Times. Retrieved 11 (2015)
7/ Al-Tawfiq, Jaffar A., AlimuddinZumla, and Ziad A. Memish. "Travel implications of emerging coronaviruses: SARS and MERS-CoV." Travel medicine and infectious disease 12.5 (2014):422-428.
8/ Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet.2020;395(10223):507-513.
9/ Pfefferbaum, Betty, and Carol S. North.” Mental health and the Covid-19 pandemic." New England Journal of Medicine 383.6 (2020): 510-512.
10/Gharizadeh, Baback, et al. "Navigating the pandemic response life cycle: molecular diagnostics and immunoassays in the context of COVID-19 management." IEEE reviews in biomedical engineering 14 (2020): 30-47.
11/ Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course
and risk factors for mortality of adult inpatients with COVID- 19 in Wuhan, China: a retrospective cohort study. Lancet.2020;395(10229):1054–62.
12/ Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 Does Not Lead to a "Typical" Acute
Respiratory Distress Syndrome. Am J RespirCrit Care Med.
13/ L. Gattinoni, et al., Covid-19 does not lead to a “Typical” acute respiratory distress syndrome, Am. J. Respir. Crit. Care Med. (2020), and I. Szalkai, et al., Possibilities of pre-hospital intervention in the prevention and treatment of Covid-19 recommendations of the Hungarian integrative medicine association, J. Med. Healthcare SRC/JMHC/118 (2020).
14/ Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 Does Not Lead to a "Typical" AcuteRespiratory Distress Syndrome. Am J RespirCrit Care Med. 2020;201(10):1299–1300
15/ Lang M, Som A, Mendoza DP, Flores EJ, Reid N, Carey D, et al.Hypoxemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. Lancet Infect Dis. 2020 (in
press).
16/ W. Liu, H. Li, COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism, ChemRxiv (2020)
17/ Singh, Aminder, et al. "Morphology of COVID-19–affected cells in peripheral blood film." BMJ Case Reports CP 13.5 (2020): e236117.
18/ Wang K, Chen W, Zhou Y, et al. SARS -CoV- 2 invades host cells via a novel
route: CD147-spike protein. BioRxiv 2020.03.14.988345
19/ Radzikowska U, Ding M, Tan G, et al.Distribution of ACE2, CD147, cyclophilins, CD26 and other SARSCoV-2 associated molecules in human tissues and immune cells in health anddisease. bioRxiv
20/ Ulrich, H, Pillat M. CD147 as a Targetfor COVID-19 Treatment: Suggested
Effects of Azithromycin and Stem Cell Engagement. Stem Cell Rev Rep 2020
21/ Li Y, Zhang Z, Yang L, et al.TheMERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2spike.iScience 2020;101160
22/ O’Leary H, Ou X, Broxmeyer HE. Therole of dipeptidyl peptidase 4 in hematopoiesis and transplantation.CurrOpinHematol 2013; 20:314-19.
23/ Liu, Wenzhong, and Hualan Li. "COVID-19: Attacks the 1-beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Heme Metabolism." Am Chem Soc (2020).
24/ T. Yoshida, G. Kikuchi. Features of the reaction of heme degradation catalyzed by the reconstituted microsomal heme. oxygenase system, J. Biol. Chem. 253 (1978) 4230–4236.
25/ T. Yoshida, M. Noguchi, G. Kikuchi, Oxygenated form of heme.Hem oxygenase complex and requirement for second electron to initiate heme degradation from the oxygenated complex, J. Biol. Chem. 255 (1980) 4418–4420
26/ R.M. Davydov, T. Yoshida, M. Ikeda-Saito, B.M. Hoffman, Hydroperoxy-hemeoxygenase generated by cryoreduction catalyzes the formation of a-meso-hydroxyheme as detected by EPR and ENDOR, J. Am. Chem. Soc. 121 (1999) 10656–10657.
27/ T. Yoshida, G. Kikuchi, features of the reaction of heme degradation catalyzed by the reconstituted microsomal hem oxygenase system, J. Biol. Chem. 253 (1978) 4230–4236.
28/ Kikuchi, Goro, Tadashi Yoshida, and Masato Noguchi. "Heme oxygenase and heme degradation." Biochemical and biophysical research communications 338.1 (2005): 558-567.
29/ Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil PA. Harper’s Illustrated Biochemistry. 28th ed. United States: Lange medical book; 2009.
30/ Hoffbrand AV, Moss PH. Hoffbrand’s Essential Hematology. 7th ed. Chichester: Wiley Blackwell; 2016.
31/ Barrett KE, Barman SM, Brooks HL, Yuan J. Ganong’s Review of Medical Physiology. 26th ed. United States: Lange medical book; 2019.
32/ Weber, Roy E., et al. "Modulation of red cell glycolysis: interactions between vertebrate hemoglobin and cytoplasmic domains of band 3 red cell membrane proteins." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 287.2 (2004): R454-R464.
33/ Cooling L. Blood Groups in Infection and Host Susceptibility. ClinMicrob Rev 2015; 28:801-70.
34/ Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, cyclophilins, CD26 and other SARSCoV-2 associated molecules in humantissues and immune cells in health and disease. bioRxiv 2020.05.14.090332
35Muramatsu T. Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. JBiochem 2016; 159:481-90.